RU 486/prostaglandin: considerations for appropriate use in low-resource settings.
Holt
R
R
D000021:Abortifacient Agents, Steroidal / Q000009:adverse effects; D000328:Adult; D003257:Consumer Product Safety; D018864:Cultural Diversity; D003906:Developing Countries; D017277:Drug Approval; D016527:Drug Costs; D004357:Drug Synergism; D005060:Europe; D005260:Female; D005602:France; D006297:Health Services Accessibility; D006801:Humans; D033181:Information Dissemination; D038622:Internationality; D008428:Maternal Mortality; D015735:Mifepristone / Q000009:adverse effects*; D018579:Patient Selection; D011247:Pregnancy; D037841:Pregnant People; D011459:Prostaglandins E, Synthetic / Q000009:adverse effects; D018570:Risk Assessment; D012926:Social Control, Formal; D014481:United States; D014619:Vacuum Curettage / Q000009:adverse effects; D035862:Vulnerable Populations
D000021:Abortifacient Agents, Steroidal; D011459:Prostaglandins E, Synthetic; D015735:Mifepristone